WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2000061167) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-$g(k)B ACTIVITY INHIBITORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2000/061167    International Application No.:    PCT/US2000/009121
Publication Date: 19.10.2000 International Filing Date: 07.04.2000
Chapter 2 Demand Filed:    09.10.2000    
IPC:
A61K 31/165 (2006.01), A61K 31/166 (2006.01), A61K 31/40 (2006.01), A61K 31/435 (2006.01), A61K 31/66 (2006.01), A61K 38/05 (2006.01), A61K 38/06 (2006.01)
Applicants: OSTEOSCREEN, INC. [US/US]; Suite 201, 2040 Babcock Road, San Antonio, TX 78229 (US)
Inventors: MUNDY, Gregory, R.; (US)
Agent: FAVORITO, Carolyn; Morrison & Foerster LLP, 2000 Pennsylvania Avenue, N.W., Washington, DC 20006-1888 (US).
GOLDIN, Douglas, Michael; J.A. Kemp & Co., 14 South Square, Gray's Inn, London WC1R 5LX (GB)
Priority Data:
09/289,229 09.04.1999 US
Title (EN) TREATMENT OF MYELOMA BONE DISEASE WITH PROTEASOMAL AND NF-$g(k)B ACTIVITY INHIBITORS
(FR) TRAITEMENT DU SYNDROME MYELOPROLIFERATIF AU MOYEN D'INHIBITEURS DE L'ACTIVITE DES PROTEASOMES ET DE NF-$g(k)B
Abstract: front page image
(EN)The present invention involves the identification and use of compositions for treating myeloma bone disease. The compositions inhibit proteasomal activity and decrease the activity of the transcription factor NF-$g(k)B. Assessment of a candidate compound for its ability to inhibit production or activity of proteasomal enzymes or NF-$g(k)B provides a useful means to identify agents to treat myeloma bone disease.
(FR)L'invention concerne l'identification et l'utilisation de compositions pour le traitement du syndrome myéloprolifératif. Lesdites compositions inhibent l'activité des protéasomes et réduisent l'activité du facteur de transcription NF-$g(k)B. L'évaluation de la capacité d'un composé d'intérêt potentiel à inhiber la production ou l'activité d'enzymes protéasomes ou de NF-$g(k)B permet l'identification efficace d'agents pour le traitement du syndrome myéloprolifératif.
Designated States: AU, CA, JP.
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
Publication Language: English (EN)
Filing Language: English (EN)